Pretreatment Tumor-infiltrating CD8 + T Cell Numbers Are Associated With the Response to Tremelimumab Plus Durvalumab in Hepatocellular Carcinoma
Anticancer Research · 2026
DOI: 10.21873/anticanres.18267 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Akifumi Kuwano und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan; akuwanoh1@aih-net.com. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan; akuwanoh1@aih-net.com.
- Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan.
- Department of Gastroenterology, Ichinomiyanishi Hospital, Ichinomiya, Japan.
- Department of Diagnostic Pathology, Aso Iizuka Hospital, Iizuka, Japan.
Zitieren
APA
Kuwano, A., Yada, M., Tanaka, K., Hamamoto, T., Kurosaka, K., Suzuki, H., Ohishi, Y., & Motomura, K. (2026). Pretreatment Tumor-infiltrating CD8 + T Cell Numbers Are Associated With the Response to Tremelimumab Plus Durvalumab in Hepatocellular Carcinoma. Anticancer Research. https://doi.org/10.21873/anticanres.18267
Vancouver
Kuwano A, Yada M, Tanaka K, Hamamoto T, Kurosaka K, Suzuki H, et al. Pretreatment Tumor-infiltrating CD8 + T Cell Numbers Are Associated With the Response to Tremelimumab Plus Durvalumab in Hepatocellular Carcinoma. Anticancer Research. 2026. doi:10.21873/anticanres.18267
BibTeX
@article{Kuwano2026,
author = {Kuwano, Akifumi and Yada, Masayoshi and Tanaka, Kosuke and Hamamoto, Taikan and Kurosaka, Kazuki and Suzuki, Hideo and Ohishi, Yoshihiro and Motomura, Kenta},
title = {Pretreatment Tumor-infiltrating CD8 + T Cell Numbers Are Associated With the Response to Tremelimumab Plus Durvalumab in Hepatocellular Carcinoma},
journal = {Anticancer Research},
year = {2026},
doi = {10.21873/anticanres.18267}
}
EUVIMED